抗抑郁药物引起的药物性肝损伤的不良事件概况:比例失调分析。

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Drug Safety Pub Date : 2024-05-06 eCollection Date: 2024-01-01 DOI:10.1177/20420986241244585
Aidou Jiang, Chunyan Wei, Weiwei Zhu, Fengbo Wu, Bin Wu
{"title":"抗抑郁药物引起的药物性肝损伤的不良事件概况:比例失调分析。","authors":"Aidou Jiang, Chunyan Wei, Weiwei Zhu, Fengbo Wu, Bin Wu","doi":"10.1177/20420986241244585","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antidepressants are widely used to manage depression and other psychiatric diseases. A previous study revealed that hepatotoxicity was the main adverse event related to antidepressants. Therefore, drug-induced liver injury (DILI) caused by antidepressants deserves more attention.</p><p><strong>Objectives: </strong>To investigate DILI adverse events reported due to antidepressant use in the United States Food and Drug Administration Adverse Events Reporting System (FAERS) database.</p><p><strong>Research design: </strong>A disproportionality analysis of spontaneously reported adverse events was conducted to assess the association between antidepressant drugs and DILI.</p><p><strong>Methods: </strong>FAERS data from 1 January 2004 to 31 December 2021 were compiled and analyzed using the reporting odds ratio (ROR) and information component (IC).</p><p><strong>Results: </strong>As per the FAERS database, of the 324,588 cases that were administered antidepressants, 10,355 were identified as cases with DILI. Among the identified 42 antidepressants, nefazodone (<i>n</i> = 47, ROR = 7.79, IC = 2.91), fluvoxamine (<i>n</i> = 29, ROR = 4.69, IC = 2.20), and clomipramine (<i>n</i> = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin (<i>n</i> = 3, ROR = 21.46, IC = 3.99), nefazodone (<i>n</i> = 264, ROR = 18.67, IC = 3.84), and maprotiline (<i>n</i> = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone (<i>n</i> = 187, ROR = 12.71, IC = 0.48), clomipramine (<i>n</i> = 35, ROR = 2.07, IC = 0.26), and mirtazapine (<i>n</i> = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders. Only nefazodone elicited hepatic failure signals (<i>n</i> = 48, ROR = 18.64, IC = 4.16). There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine.</p><p><strong>Conclusion: </strong>A significant association was observed between DILI and nefazodone. Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite causal link between antidepressants and DILI. Additional research is required to assess new-generation antidepressants for their propensity to cause DILI.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":"15 ","pages":"20420986241244585"},"PeriodicalIF":3.4000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075604/pdf/","citationCount":"0","resultStr":"{\"title\":\"Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.\",\"authors\":\"Aidou Jiang, Chunyan Wei, Weiwei Zhu, Fengbo Wu, Bin Wu\",\"doi\":\"10.1177/20420986241244585\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antidepressants are widely used to manage depression and other psychiatric diseases. A previous study revealed that hepatotoxicity was the main adverse event related to antidepressants. Therefore, drug-induced liver injury (DILI) caused by antidepressants deserves more attention.</p><p><strong>Objectives: </strong>To investigate DILI adverse events reported due to antidepressant use in the United States Food and Drug Administration Adverse Events Reporting System (FAERS) database.</p><p><strong>Research design: </strong>A disproportionality analysis of spontaneously reported adverse events was conducted to assess the association between antidepressant drugs and DILI.</p><p><strong>Methods: </strong>FAERS data from 1 January 2004 to 31 December 2021 were compiled and analyzed using the reporting odds ratio (ROR) and information component (IC).</p><p><strong>Results: </strong>As per the FAERS database, of the 324,588 cases that were administered antidepressants, 10,355 were identified as cases with DILI. Among the identified 42 antidepressants, nefazodone (<i>n</i> = 47, ROR = 7.79, IC = 2.91), fluvoxamine (<i>n</i> = 29, ROR = 4.69, IC = 2.20), and clomipramine (<i>n</i> = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin (<i>n</i> = 3, ROR = 21.46, IC = 3.99), nefazodone (<i>n</i> = 264, ROR = 18.67, IC = 3.84), and maprotiline (<i>n</i> = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone (<i>n</i> = 187, ROR = 12.71, IC = 0.48), clomipramine (<i>n</i> = 35, ROR = 2.07, IC = 0.26), and mirtazapine (<i>n</i> = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders. Only nefazodone elicited hepatic failure signals (<i>n</i> = 48, ROR = 18.64, IC = 4.16). There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine.</p><p><strong>Conclusion: </strong>A significant association was observed between DILI and nefazodone. Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite causal link between antidepressants and DILI. Additional research is required to assess new-generation antidepressants for their propensity to cause DILI.</p>\",\"PeriodicalId\":23012,\"journal\":{\"name\":\"Therapeutic Advances in Drug Safety\",\"volume\":\"15 \",\"pages\":\"20420986241244585\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075604/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20420986241244585\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986241244585","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:抗抑郁药被广泛用于治疗抑郁症和其他精神疾病。先前的一项研究显示,肝毒性是与抗抑郁药相关的主要不良反应。因此,抗抑郁药引起的药物性肝损伤(DILI)值得更多关注:调查美国食品和药物管理局不良事件报告系统(FAERS)数据库中报告的因使用抗抑郁药而导致的DILI不良事件:研究设计:对自发报告的不良事件进行比例失调分析,以评估抗抑郁药物与DILI之间的关联:方法:汇编2004年1月1日至2021年12月31日的FAERS数据,并使用报告几率比(ROR)和信息成分(IC)进行分析:根据 FAERS 数据库,在 324,588 例服用抗抑郁药物的病例中,有 10,355 例被确定为 DILI 病例。在已确定的 42 种抗抑郁药中,奈法唑酮(n = 47,ROR = 7.79,IC = 2.91)、氟伏沙明(n = 29,ROR = 4.69,IC = 2.20)和氯米帕明(n = 24,ROR = 3.97,IC = 1.96)的胆汁淤积性损伤 ROR 最高;米安色林(n = 3,ROR = 21.46,IC = 3.99)、奈法唑酮(n = 264,ROR = 18.67,IC = 3.84)和马普替林(n = 15,ROR = 5.65,IC = 2.39)导致肝细胞损伤;奈法唑酮(n = 187,ROR = 12.71,IC = 0.48)、氯米帕明(n = 35,ROR = 2.07,IC = 0.26)和米氮平(n = 483,ROR = 1.96,IC = 0.94)导致严重的药物相关肝功能紊乱。只有奈法唑酮出现肝功能衰竭信号(n = 48,ROR = 18.64,IC = 4.16)。关于相对较新的抗抑郁药物(如米那西普兰、维洛沙嗪、艾司卡胺和替安肽)以及未获美国食品药品管理局批准的药物(如瑞博西汀和阿戈美拉汀)的不良反应报告有限:结论:观察到 DILI 与奈法唑酮之间存在明显关联。除肝功能衰竭外,度洛西汀和氯米帕明与三类 DILI 相关。比例失调分析不能得出抗抑郁药与 DILI 之间存在明确因果关系的结论。还需要开展更多研究,评估新一代抗抑郁药导致 DILI 的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.

Background: Antidepressants are widely used to manage depression and other psychiatric diseases. A previous study revealed that hepatotoxicity was the main adverse event related to antidepressants. Therefore, drug-induced liver injury (DILI) caused by antidepressants deserves more attention.

Objectives: To investigate DILI adverse events reported due to antidepressant use in the United States Food and Drug Administration Adverse Events Reporting System (FAERS) database.

Research design: A disproportionality analysis of spontaneously reported adverse events was conducted to assess the association between antidepressant drugs and DILI.

Methods: FAERS data from 1 January 2004 to 31 December 2021 were compiled and analyzed using the reporting odds ratio (ROR) and information component (IC).

Results: As per the FAERS database, of the 324,588 cases that were administered antidepressants, 10,355 were identified as cases with DILI. Among the identified 42 antidepressants, nefazodone (n = 47, ROR = 7.79, IC = 2.91), fluvoxamine (n = 29, ROR = 4.69, IC = 2.20), and clomipramine (n = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin (n = 3, ROR = 21.46, IC = 3.99), nefazodone (n = 264, ROR = 18.67, IC = 3.84), and maprotiline (n = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone (n = 187, ROR = 12.71, IC = 0.48), clomipramine (n = 35, ROR = 2.07, IC = 0.26), and mirtazapine (n = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders. Only nefazodone elicited hepatic failure signals (n = 48, ROR = 18.64, IC = 4.16). There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine.

Conclusion: A significant association was observed between DILI and nefazodone. Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite causal link between antidepressants and DILI. Additional research is required to assess new-generation antidepressants for their propensity to cause DILI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
期刊最新文献
Investigating the impact of a pharmacist intervention on inappropriate prescribing practices at hospital admission and discharge in older patients: a secondary outcome analysis from a randomized controlled trial. Determining the optimum dose of remifentanil in combination with propofol for total intravenous anaesthesia in hysteroscopy under Narcotrend and SPI monitoring. The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey. Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1